SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is surging following a strong quarterly beat and raise, with the community actively discussing a shift in market perception as the company rebrands itself as a core player in AI infrastructure. Investors are debating the sustainability of this momentum, weighing concerns about capital intensity and valuation against excitement for a potential long-term CPU renaissance and foundry strategy execution.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging to record highs, driven by investor enthusiasm following Intel's earnings beat and broad sector rotation into semiconductor and AI-focused infrastructure plays. While the community is split between bullish sentiment over long-term AI megatrends and concerns regarding potential overvaluation, many traders are closely watching for continued momentum into the upcoming earnings cycle.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The semiconductor sector's relentless rally has left investors heavily debating the viability of SOXS, as many are struggling with significant losses while the underlying index continues to hit new highs without a meaningful pullback. Community sentiment is deeply divided between those calling for an imminent, violent reversal and others warning that volatility decay makes this inverse, leveraged instrument a dangerous long-term hold.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing massive volatility driven by extreme AI chip demand, a semiconductor supply "super cycle," and intense community debate over whether the surge represents a historic bubble or a persistent, momentum-driven melt-up. While bulls are riding the parabolic trend with high-leverage positions and dismissing pullbacks, skeptics are actively shorting the symbol, citing comparisons to past market manias and unsustainable valuation levels.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors debate its massive market cap against high-growth semiconductor peers like AMD and Intel, with the community closely tracking its strategic partnerships and the broader impact of AI infrastructure demand. Discussion remains polarized, with many retail traders frustrated by the stock's recent sideways movement compared to the wider chip sector, while others argue that its dominant ecosystem position makes it a long-term anchor for the AI trade.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing extreme volatility and massive trading volume following a jury verdict that awarded the company over $1 billion in damages and disgorgement against a rival for fraudulent bot usage. The community is heavily focused on the potential for a major short squeeze due to the company's tight float and the significant legal catalyst, with traders debating whether to hold for triple-digit gains or exit into the intense retail-driven momentum.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as investors react to confirmed production orders linked to Marvell and broader expectations that its optical interposer platform is becoming critical to AI data center infrastructure. The community is actively debating the stock's transition from speculative R&D to commercial execution, with strong enthusiasm regarding hyperscale partnerships and the potential for the company to become an industry standard in optical connectivity.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is seeing extreme volatility as investors grapple with a massive sell-off following a rapid price surge, sparking intense debate over whether the stock is undergoing a fundamental correction or setting up for another short squeeze. The community remains deeply divided, with bears pointing to the company's significant debt load and potential securities investigations as red flags, while some bulls are actively searching for signs of a technical rebound or renewed institutional buying interest.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility driven by speculative trading around Middle East ceasefire headlines and ongoing semiconductor sector concentration. Investors are actively debating whether the current rally is a sustainable AI-led bull cycle or a precarious bubble vulnerable to geopolitical shocks and unsustainable valuation levels.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors react to volatility driven by the company's expansion into GLP-1 treatments and broader market concerns regarding potential competition from Amazon. The community remains divided, with bullish participants pointing to strong subscriber growth and platform potential as a catalyst for a short squeeze, while bears highlight valuation concerns and the impact of the competitive landscape on margins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data

Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.

Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?

Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the stock, MarketBeat reports...

Kura Oncology (NASDAQ:KURA) Stock Price Up 9.7% - Time to Buy?

Kura Oncology (NASDAQ:KURA) Trading Up 9.7% - Here's What Happened...

Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results

Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; analysts maintain Buy ratings.read more...

<ul class="summary-bullets"><li>The treatment showed an objective response rate of 44% and a disease control rate of 94%.</li><li>Kura said tumor shrinkage was seen in 75% of the 16 patients on trial.</li><li>The results were presented at the International Kidney Cancer Symposium Europe 2026 in Paris.</li></ul>Shares of Kura Oncology (KURA) jumped more than 13% in pre-market trading on Friday after the clinical-stage biotech firm reported encouraging early data from its ongoing trial for the treatment of advanced kidney cancer.The results, presented at the International Kidney Cancer Symposium Europe 2026 in Paris, focused on patients with clear cell renal cell carcinoma (ccRCC).If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/KURA">KURA shares</a> would hit their highest levels since Jan. 7, 2026.<h2 class="st-heading-2">Strong Response Rates, But Small Sample Size</h2>Kura shared initial results from an ongoing FIT-001 trial testing its investigational therapy, Darlifarnib, in combination with Cabozantinib, a type of target enzyme inhibitor, in kidney cancer patients who had already been treated with Cabozantinib.The treatment showed an objective response rate of 44% and a disease control rate of 94%. Tumor shrinkage was seen in 75% of patients, including those who had previously shown limited response to Cabozantinib.Of the 16 patients receiving treatment over an 8- to 56-week period, six are still receiving therapy at the time of the analysis, the company said.<h2 class="st-heading-2">What Investors Should Watch Next</h2>The treatment also demonstrated a manageable safety profile across different dose levels. The study is testing Darlifarnib at daily doses of 3 mg, 5 mg, or 8 mg, taken in cycles of 7 days on and 7 days off, along with daily Cabozantinib at 60 mg or 40 mg. All patients in the study have previously received immunotherapy.The study is now advancing into Phase 1b to further evaluate the optimal dosing and potential benefits of the regimen.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the run-up to start soon.<stembedurl>https://stocktwits.com/mulc/message/650490176</stembedurl>Another user expects “positive news” from the company’s conference call.<stembedurl>https://stocktwits.com/Georgeson/message/650542576</stembedurl>Year-to-date, the stock has shed around 15%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

KURA Stock Pops After Promising Early Cancer Data — What Investors Should Know

The biotech firm reported encouraging early data from its ongoing trial for advanced kidney cancer.

Why Did KURA Stock Jump 13% In Pre-Market Today?

Equity

Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lake Street Capital

Lake Street Capital upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday...

Kura Oncology (NASDAQ:KURA) Trading Up 4.8%  - Here's What Happened

Kura Oncology (NASDAQ:KURA) Stock Price Up 4.8% - Should You Buy...

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume  - Time to Buy?

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume - Should You Buy...

Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

KURA
Kura Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News

KURAKura Oncology Inc